Cyprotex PLC (“Cyprotex” or “the Company”)
Cyprotex Announces Free Access to Physicochemical, ADME, and Pharmacokinetic Data of Marketed Drugs Through Its Visualisation Tool, Cloe® Knowledge
Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that it is making available to researchers free online access to Cyprotex’s database of the ADME and pharmacokinetic properties of marketed drugs via its online Cloe® Knowledge data visualisation and interpretation tool.
Free access is available via Cyprotex’s Cloe® Gateway online portal: www.cloegateway.com.
Cloe® Knowledge categorises marketed drugs according to the 2009 WHO ATC/DDD drug index, allowing the database to be searchable by therapeutic area. Cloe® Knowledge’s compound property visualisation tools allow relationships between different ADME and phys-chem properties to be viewed on either 2D or 3D scatter plots.
Commenting on the announcement, Dr Anthony D Baxter, Cyprotex's Chief Executive Officer, said:
“Cyprotex believes in sharing its knowledge with the scientific community. Our Cloe® Knowledge database of marketed drugs has been compiled and continuously updated based on extensive literature values and data generated in our own laboratories. Although some of the data are already available in the public domain, often they have not been conveniently compiled, and certainly not accessible through a powerful visualisation and interpretation tool such as the one Cloe® Knowledge provides. We believe that free access to these data via Cloe® Knowledge will help advance drug discovery, especially within the resource-constrained academic community.”
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Tel: +44 (0) 1625 505 100
Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 203 205 7500
Tel: +44 (0) 20 7831 3113